Join Arrowhead Pharmaceuticals for Part III of its 2024 Summer Series of R&D Webinars, featuring Matthias A. Salathe, MD (University of Kansas Medical Center). Arrowhead management will provide updates on its key pulmonary programs in Phase 1/2 development:

• ARO-RAGE, designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases.
• ARO-MMP7, designed to the reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
• ARO-MUC5AC, designed to reduce production of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases.

A live question and answer session will follow the formal presentation.